[go: up one dir, main page]

GB201818110D0 - Monocytes for cancer targeting - Google Patents

Monocytes for cancer targeting

Info

Publication number
GB201818110D0
GB201818110D0 GBGB1818110.7A GB201818110A GB201818110D0 GB 201818110 D0 GB201818110 D0 GB 201818110D0 GB 201818110 A GB201818110 A GB 201818110A GB 201818110 D0 GB201818110 D0 GB 201818110D0
Authority
GB
United Kingdom
Prior art keywords
monocytes
cancer targeting
targeting
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1818110.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrophox Ltd
Original Assignee
Macrophox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrophox Ltd filed Critical Macrophox Ltd
Priority to GBGB1818110.7A priority Critical patent/GB201818110D0/en
Publication of GB201818110D0 publication Critical patent/GB201818110D0/en
Priority to PCT/GB2019/053140 priority patent/WO2020095044A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1818110.7A 2018-11-06 2018-11-06 Monocytes for cancer targeting Ceased GB201818110D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1818110.7A GB201818110D0 (en) 2018-11-06 2018-11-06 Monocytes for cancer targeting
PCT/GB2019/053140 WO2020095044A1 (en) 2018-11-06 2019-11-06 Monocytes for cancer targeting

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1818110.7A GB201818110D0 (en) 2018-11-06 2018-11-06 Monocytes for cancer targeting

Publications (1)

Publication Number Publication Date
GB201818110D0 true GB201818110D0 (en) 2018-12-19

Family

ID=64655458

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1818110.7A Ceased GB201818110D0 (en) 2018-11-06 2018-11-06 Monocytes for cancer targeting

Country Status (2)

Country Link
GB (1) GB201818110D0 (en)
WO (1) WO2020095044A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
WO2021046243A2 (en) 2019-09-03 2021-03-11 Myeloid Therapeutics, Inc. Methods and compositions for genomic integration
BR112022011339A2 (en) * 2019-12-11 2022-10-04 Myeloid Therapeutics Inc COMPOSITIONS OF THERAPEUTIC CELLS AND METHODS FOR MANUFACTURING AND USING THEM
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
JP2023549140A (en) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド Engineered chimeric fusion protein compositions and methods of use thereof
GB202019108D0 (en) * 2020-12-03 2021-01-20 Ospedale San Raffaele Srl Vector
EP4308133A4 (en) 2021-03-17 2025-01-22 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
KR20240037192A (en) 2021-05-11 2024-03-21 마이얼로이드 테라퓨틱스, 인크. Methods and compositions for genome integration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010007659A1 (en) * 1997-04-17 2001-07-12 The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
US20090123366A1 (en) * 2006-04-03 2009-05-14 Keele University Targeted Therapy
WO2012005763A1 (en) * 2010-07-06 2012-01-12 The Scripps Research Institute Use of myeloid-like progenitor cell populations to treat tumors
CN105407902A (en) * 2013-03-05 2016-03-16 贝勒医学院 Oncolytic virus
WO2016146894A1 (en) * 2015-03-17 2016-09-22 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
US10525082B2 (en) * 2015-09-09 2020-01-07 Seattle Children's Hospital Genetic engineering of macrophages for immunotherapy

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
AHN G-O ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 18, May 2010 (2010-05-01), pages 8363 - 8368
AZIZI ET AL., CELL, vol. 174, August 2018 (2018-08-01), pages 1293 - 1308
COBOS-JIMENEZ ET AL., PHYSIOL GENOMICS, vol. 46, 2014, pages 91 - 103
DVORAK, NEW ENGLAND J MEDICINE, vol. 315, no. 26, 1986, pages 1650 - 9
ELLIOT ET AL., FRONTIERS IN IMMUNOLOGY, vol. 8, 2017
FRANKLIN; AND LI, TRENDS CANCER, vol. 2, no. 1, 2016, pages 20 - 34
FRASER ET AL., CYTOTHERAPY, vol. 19, no. 9, September 2017 (2017-09-01), pages 1113 - 1124
MILLER ET AL., SCIENCE TRANSLATIONAL MEDICINE, vol. 9, no. 392, 2017
MUHLEBACH ET AL., MOLECULAR THERAPY, vol. 12, no. 6, 2005, pages 1206 - 16
NATURE METHODS, vol. 5, no. 1, 2008, pages 16 - 18
SHIAO SL ET AL., CANCER IMMUNOL RES., vol. 3, no. 5, pages 518 - 525

Also Published As

Publication number Publication date
WO2020095044A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination cancer therapy
GB201818110D0 (en) Monocytes for cancer targeting
IL254705A0 (en) Combination therapy for cancer
SG10201913631TA (en) Rna for cancer therapy
IL287644A (en) Cytarabine conjugates for cancer therapy
ZA202005847B (en) Cancer therapy
IL292272A (en) Cancer vaccine
IL282093A (en) Combination therapy for cancer
EP3347098A4 (en) TARGETING MDA-5 ACTIVATION FOR CANCER IMMUNOTHERAPY
GB201905780D0 (en) Cancer therapy
EP3576746A4 (en) Cancer therapeutic
GB2580963C (en) Cancer therapies
GB201814487D0 (en) Cancer
GB201800733D0 (en) Cancer
GB201913957D0 (en) Cancer
GB201820626D0 (en) Conjugates
GB201704909D0 (en) Cancer therapy
GB201703907D0 (en) Novel therapies for cancer
IL259097A (en) Combination therapy for cancer
GB201711855D0 (en) Cancer therapy
IL282030A (en) Antibodies targeting epn1
GB201901991D0 (en) Cancer
HK40058839A (en) Combination therapy for cancer
HK40057716B (en) Combination therapy for cancer
HK40025983A (en) Castration resistant prostate cancer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)